The European Citizens’ Initiative for Psychedelic-Assisted Therapies – launching at the start of 2025 – is aiming to collect one million signatures to urge the European...
Awakn Life Sciences has entered into a new collaboration with Graft Polymer to advance its New Chemical Entity (NCE) programme, developing novel molecules for innovative addiction...
A new proof-of-concept pilot study by Onaya Science found that participation in ayahuasca retreats carried out in a traditional Indigenous Amazonian context was associated with significant...
The UK’s independent Parliamentary Office of Science and Technology (POST) has issued a rapid response on psychedelic-assisted therapy for anxiety disorders.
Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges.
The Psychedelic Access and Research European Alliance (PAREA) has launched a policy paper in line with a recent meeting on medical psychedelics in the European Parliament.
Mind Medicine has confirmed it has completed enrollment of Study MMED007, its Phase 2a study evaluating repeated low-dose administration of MM-120 (LSD) for the treatment of...
Results from a new analysis have revealed an improvement in mental health and cognition for Special Operations Forces veterans following a combination of psychedelic treatments.
Results from the world’s largest study investigating the ‘naturalistic’ use of psilocybin outside of research settings have shown lasting therapeutic benefits.
Findings from a landmark survey have revealed that people with experience using psychedelics exhibited elevated psychological well-being during the COVID-19 pandemic.
